Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803 stimulation for NK cell expansion in healthy donors
NCT06040918Phase 1Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Oct 2023
- Primary completion
- Sep 2024
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nogapendekin alfa inbakicept, sponsored by ImmunityBio, Inc. Primary endpoint: Incidence of serious adverse events and overall adverse events coded in MedDRA at 45 days. Started Oct 2023; status: completed.
02
Drugs
nogapendekin alfa inbakicept
Beyond the preview
Go deeper on NCT06040918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06040918.